Scholar Rock Holding Dirección

Dirección controles de criterios 4/4

El CEO de Scholar Rock Holding's es Jay Backstrom , nombrado en Oct 2022, tiene una permanencia de 1.5 años. compensación anual total es $7.50M, compuesta por 2.1% salario y 97.9% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.032% de las acciones de la empresa, por valor de $362.39K. La antigüedad media del equipo directivo y de la junta directiva es de 2.1 años y 7.5 años, respectivamente.

Información clave

Jay Backstrom

Chief Executive Officer (CEO)

US$4.1m

Compensación total

Porcentaje del salario del CEO	15.2%
Permanencia del CEO	1.6yrs
Participación del CEO	0.03%
Permanencia media de la dirección	2.2yrs
Promedio de permanencia en la Junta Directiva	7.6yrs

Actualizaciones recientes de la dirección

Recent updates

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Apr 15

Scholar Rock: Solid Data And Good Prospects

Jan 12

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Apr 19

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Oct 20

Jay Backstrom is the new CEO at Scholar Rock

Sep 20

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Jul 12

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

May 21

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Mar 08

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be

May 15

Is Scholar Rock Holding (NASDAQ:SRRK) Using Too Much Debt?

May 07

If You Had Bought Scholar Rock Holding (NASDAQ:SRRK) Stock A Year Ago, You Could Pocket A 283% Gain Today

Mar 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jay Backstrom en comparación con los beneficios de Scholar Rock Holding?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$183m
Dec 31 2023	US$4m	US$624k	-US$166m
Sep 30 2023	n/a	n/a	-US$159m
Jun 30 2023	n/a	n/a	-US$160m
Mar 31 2023	n/a	n/a	-US$166m
Dec 31 2022	US$7m	US$159k	-US$135m

Compensación vs. Mercado: La compensación total ($USD4.11M) de Jay está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD5.72M).

Compensación vs. Ingresos: La compensación de Jay ha sido consistente con los resultados de la empresa en el último año.

CEO

Jay Backstrom (68 yo)

1.6yrs

Permanencia

US$4,111,853

Compensación

Dr. Jay Thomas Backstrom, M.D., M.P.H., serves as Non-Executive Director of LAVA Therapeutics N.V. since June 2022. He serves as Director at Be Biopharma, Inc. since December 2021. He had served as a Direc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Backstrom	President	1.6yrs	US$4.11m	0.032% $ 375.4k
Edward Myles	CFO, COO & Treasurer	3.8yrs	US$2.01m	0.031% $ 362.1k
Tracey Sacco	Chief Commercial Officer	1.3yrs	US$2.28m	0% $ 0
Mo Qatanani	Chief Scientific Officer	less than a year	sin datos	0.013% $ 151.5k
Rushmie Nofsinger	Vice President of Corporate Affairs & Investor Relations	no data	sin datos	sin datos
Junlin Ho	General Counsel & Corporate Secretary	4.2yrs	US$2.13m	0.080% $ 924.9k
Caryn Parlavecchio	Chief Human Resources Officer	2.8yrs	sin datos	0.037% $ 427.2k
Lisa Price	Senior Vice President of Human Resources	no data	sin datos	sin datos
Erin Moore	Senior Vice President of Finance	no data	sin datos	sin datos
Ryan Iarrobino	Senior Vice President of Clinical Development & Operations	4.2yrs	sin datos	sin datos
Jing Marantz	Chief Medical Officer	1.5yrs	sin datos	sin datos

2.2yrs

Permanencia media

50.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SRRK se considera experimentado (2.1 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jay Backstrom	President	1.6yrs	US$4.11m	0.032% $ 375.4k
Michael Gilman	Independent Director & Member of Scientific Advisory Board	10.5yrs	US$299.20k	0.047% $ 543.2k
Timothy Springer	Member of Scientific Advisory Board	no data	US$48.97k	sin datos
Amir Nashat	Independent Director	11.6yrs	US$295.70k	0.033% $ 386.5k
Jeffrey Flier	Independent Director & Member of Scientific Advisory Board	7.6yrs	US$305.70k	0.011% $ 130.7k
Leonard Zon	Member of Scientific Advisory Board	no data	sin datos	sin datos
Kristina Burow	Independent Director	9.8yrs	US$300.34k	0.0067% $ 77.4k
Joan Massague	Member of Scientific Advisory Board	no data	sin datos	sin datos
David Hallal	Independent Chairman of the Board	6.8yrs	US$416.70k	0.36% $ 4.2m
Scott L. Friedman	Member of Scientific Advisory Board	no data	sin datos	sin datos
Barry Coller	Member of Scientific Advisory Board	no data	sin datos	sin datos
Joshua Reed	Independent Director	3.2yrs	US$305.70k	0% $ 0

7.6yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: La junta directiva de SRRK se considera experimentada (7.5 años de antigüedad promedio).

Scholar Rock Holding Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Recent updates

Scholar Rock Holding Corporation, Annual General Meeting, Jun 27, 2024

New major risk - Shareholder dilution

Health Check: How Prudently Does Scholar Rock Holding (NASDAQ:SRRK) Use Debt?

Price target increased by 8.1% to US$26.25

New minor risk - Share price stability

New major risk - Financial position

President recently sold US$183k worth of stock

Scholar Rock Announces Management Appointments

Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management

Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity

Scholar Rock: Solid Data And Good Prospects

CFO, COO & Treasurer notifies of intention to sell stock

Senior VP & Head of Research recently sold US$295k worth of stock

CFO, COO & Treasurer notifies of intention to sell stock

Price target increased by 7.1% to US$25.71

New major risk - Revenue and earnings growth

CFO, COO & Treasurer notifies of intention to sell stock

Scholar Rock, Inc. Presents New Data from Phase 1 Dragon Trial Showing Promising Anti-Tumor Activity in Anti-Pd-1 Resistant Metastaticcc Patients and Supporting Srk-181 Continued Tolerability

Price target increased by 9.8% to US$24.00

Scholar Rock Announces to Present Clinical and Biomarker Data from the Phase 1 Dragon Trial At the Sitc 38Th Annual Meeting

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Holding Corporation has completed a Follow-on Equity Offering in the amount of $85.000006 million.

Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial

Scholar Rock Announces New Data from the Phase 2 TOPAZ Trial Extension Period Evaluating Patient Outcomes At 36 Months of Treatment with Apitegromab

Scholar Rock Holding Corporation, Annual General Meeting, Jun 21, 2023

Scholar Rock Holding Corporation's (NASDAQ:SRRK) Share Price Not Quite Adding Up

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Scholar Rock Appoints Tracey M. Sacco as Chief Commercial Officer

Price target decreased to US$22.57

Third quarter 2022 earnings released: US$0.55 loss per share (vs US$1.02 loss in 3Q 2021)

Scholar Rock Holding Corporationa Announces Recent Phase 1 Dragon Data Show Srk-181 Continues to Be Well Tolerated with Early Indications of Efficacy

Scholar Rock Appoints Jing L. Marantz as Chief Medical Officer

Scholar Rock Holding Corporation Announces New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA

Scholar Rock: OLE Data In SMA Coupled With New CEO Make It A Buy

Scholar Rock Announces Chief Executive Officer Changes

Jay Backstrom is the new CEO at Scholar Rock

Second quarter 2022 earnings released: US$1.06 loss per share (vs US$0.84 loss in 2Q 2021)

Scholar Rock Holding Corporation Appoints Srinivas Akkaraju to Board of Directors

Scholar Rock initiated at buy at Truist on platform for rare diseases and oncology

Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 2000 Growth Index

Price target decreased to US$29.00

Scholar Rock Announces New Data from the Phase 2 Topaz Trial Extension Period Evaluating Patient Outcomes After 24-Months of Treatment

Consensus revenue estimates increase by 75%

Consensus revenue estimates increase by 75%

Brokers Are Upgrading Their Views On Scholar Rock Holding Corporation (NASDAQ:SRRK) With These New Forecasts

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Scholar Rock Holding Corporation Provides Pipeline Updates

Price target decreased to US$44.67

Price target decreased to US$46.17

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues miss analyst expectations

Broker Revenue Forecasts For Scholar Rock Holding Corporation (NASDAQ:SRRK) Are Surging Higher

Scholar Rock Holding Corporation Provides Corporate Update and Highlights Priorities for 2022

Price target decreased to US$55.80

Scholar Rock Holding Corporation Announces Design of Phase 3 SAPPHIRE Clinical Trial Evaluating Apitegromab in Non-Ambulatory Patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA)

CFO & Head of Business Operations exercised options and sold US$2.8m worth of stock

Third quarter 2021 earnings released: US$1.02 loss per share (vs US$0.79 loss in 3Q 2020)

Scholar Rock Holding Corporation Presents Additional Data Analyses from the Apitegromab TOPAZ Phase 2 Trial at the World Muscle Society 2021 Virtual Congress

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.84 loss per share (vs US$0.65 loss in 2Q 2020)

Board Member notifies of intention to sell stock

Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

Scholar Rock Announces Oral Presentation of TOPAZ Phase 2 Trail Results at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock to Present Apitegromab Clinical Data from the TOPAZ Phase 2 Trial in Patients with Type 2 and 3 Spinal Muscular Atrophy at the 2021 Virtual SMA Research & Clinical Care Meeting

Scholar Rock Receives Fast Track Designation from the U.S. FDA for Apitegromab for the Treatment of Patients with Spinal Muscular Atrophy

Scholar Rock Holding Corporation to Present Trials in Progress Poster for Srk-181 Dragon Phase 1 Clinical Trial At the American Society of Clinical Oncology Annual Meeting

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.76 loss per share (vs US$0.58 loss in 1Q 2020)

Scholar Rock Holding Corporation (NASDAQ:SRRK) Analysts Are More Bearish Than They Used To Be